Market Eyes LiveGilead Sciences Inc (GILD) Stock Rating & Analysis
MELANY's data-driven read on Gilead Sciences Inc · Biological Products, (No Diagnostic Substances).
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with its portfolio centered on HIV and hepatitis B and C. Its acquisition of Pharmasset brought the hepatitis C drug Sovaldi, now part of newer standard-of-care combination regimens, and it is expanding in oncology, led by the CAR-T cell therapy Yescarta/Tecartus (from Kite) and the breast and bladder cancer therapy Trodelvy (from Immunomedics).
Why GILD scores 60/100
MELANY scores Gilead Sciences Inc 60/100 by weighing eight factors. Here is how GILD breaks down.
Whether the price looks cheap or expensive against earnings, growth, and peers.
Margins, returns on capital, and balance-sheet strength.
- Gross margin 79%
Direction and relative strength of the recent share-price trend.
- Price +9.2% above 50-day MA
History of beating or missing estimates, and where estimates are heading.
- Beat EPS estimates 4 of last 4 quarters
- Avg EPS beat +7%
What Wall Street price targets and revisions are signalling.
- Institutional net buying +4.1%
Near-term events that could move the stock.
Upside weighed against volatility and drawdown risk.
How the current rate and market regime suits this kind of company.
Key risks for GILD
- High debt-to-equity ratio 2.2x, rate-sensitive balance sheet
- No positive trailing earnings, valuation cannot be anchored to current P/E
Sector and theme context
Gilead Sciences Inc sits in the Healthcare sector theme, which MELANY currently rates 42/100 for strength. Theme strength feeds GILD's momentum and catalyst factors above.
GILD trade plan (members only)
MELANY has a full position plan for Gilead Sciences Inc: a smart entry zone, an alert level, position sizing, and quarterly review triggers. It unlocks free when you create an account.
How MELANY rates GILD
MELANY is a rules-based engine that scores every stock from 0 to 100 across eight weighted factors, then re-scores as new price, earnings, and fundamental data arrive. Gilead Sciences Inc's 60/100 reflects speculative factor weighting for its profile. Position framework managed by score-based check-ins, not a fixed holding period.
Ratings are algorithmic and change with the data. They are research and education, not personalized investment advice.
Frequently asked questions about GILD
Is Gilead Sciences Inc (GILD) a buy?
As of 2026-08-20, MELANY rated Gilead Sciences Inc Promising with a composite score of 60/100. That is a dated snapshot, not the live rating, and it is an algorithmic reading built from eight factors rather than personalized investment advice. Review the factor breakdown above and the disclaimer below before making any decision.
What is Gilead Sciences Inc's MELANY score?
Gilead Sciences Inc (GILD) has a MELANY composite score of 60/100, combining valuation, business quality, price momentum, earnings track record, analyst sentiment, catalyst setup, risk-adjusted profile, and macro fit.
How is the GILD stock rating calculated?
MELANY scores GILD from 0 to 100 across eight weighted factors using live market and fundamental data, then refreshes the rating automatically as new data arrives.
Should I buy Gilead Sciences Inc stock?
That decision is yours; Market Eyes Live does not give buy or sell advice. What the data says: MELANY rates Gilead Sciences Inc (GILD) Promising with a composite of 60/100 as of 2026-08-20. The factor breakdown above shows what is driving that, which is a better basis for a decision than any one-word verdict.
What is the GILD stock price forecast?
MELANY does not publish price targets or forecasts for GILD. Predicting a future price is exactly the kind of false precision the confidence framework avoids. Instead it scores today's setup, 60/100 across eight factors for Gilead Sciences Inc, and re-scores automatically as new price, earnings, and fundamental data arrive.
Is GILD stock overvalued or undervalued?
MELANY's valuation factor currently reads 49/100 for Gilead Sciences Inc, where a higher score means the price looks more attractive against earnings, growth, and peers. Scores in the 70s and above read as attractively priced, the mid range as roughly fair, and low scores as stretched. The factor breakdown above shows what drives GILD's read.
What price should I buy GILD at?
Rather than chasing the current price, MELANY computes a smart entry zone for GILD: the price area where risk and reward actually favor a new position, plus an alert level and position sizing. The exact levels unlock free when you create a Market Eyes Live account.
What are the risks of buying GILD stock?
The top risks MELANY currently flags for Gilead Sciences Inc: High debt-to-equity ratio 2.2x, rate-sensitive balance sheet; No positive trailing earnings, valuation cannot be anchored to current P/E. The rating on this page already weighs these against the bullish factors; see the risk-adjusted profile score in the breakdown above.
Is Gilead Sciences Inc a good long-term investment?
For long-term durability the two factors that matter most are business quality, which MELANY scores 56/100 for Gilead Sciences Inc, and earnings track record, at 83/100. The 60/100 composite blends those with six shorter-horizon factors. Durable quality at a fair price is the long-term case to test; this is research, not personalized investment advice.
Will GILD stock go up?
Nobody can promise a stock's direction, and Market Eyes Live does not predict prices. The measurable part: MELANY's price momentum factor reads 57/100 for GILD right now, and the catalyst setup factor tracks whether near-term events could move it. Both re-score automatically as the data changes.
How current is this GILD rating?
The rating on this page is a snapshot of MELANY's read as of 2026-08-20. The price shown updates live, but the score is not recomputed on this page. MELANY re-scores GILD continuously as new price, earnings, and fundamental data arrive, and that current rating is free in the app.
GILD's entry zone, live alerts, and full trade plan are free either way. The app is our flagship.